Picture of Opus Genetics logo

IRD — Opus Genetics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapMomentum Trap

Ocuphire Pharma Inc expected to post earnings of 97  cents a share - Earnings Preview

* Ocuphire Pharma Inc  OCUP.OQ   OCUP.O  is expected to show
a
rise in quarterly revenue when it reports  results on March 22
(estimated). 
    * The Farmington Hills Michigan-based  company is expected
to
report revenue of $29.445 million, according to the mean
estimate from 5 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Ocuphire Pharma Inc
is
for earnings of 97 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ocuphire
Pharma
Inc is $22​, above​ its last closing price of $3.77. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.29       -0.29      -0.22     Beat    23.7
 Jun. 30 2022  -0.33       -0.33      -0.25     Beat    24.7
 Mar. 31 2022  -0.34       -0.35      -0.35     Met     0​
 Dec. 31 2021  -0.20       -0.29      -0.35     Missed  -22.1
 ​​Sep.        -0.39       -0.36      -0.25     Beat    30.2
 30 2021                                                
 Jun. 30 2021  -0.36       -0.36      -0.52     Missed  -43.1​
 Mar. 31 2021  -0.70       -0.71      -0.47     Beat    34
 Dec. 31 2020  -0.42       -0.42      -5.18     Missed  -1,133
                                                        .3
 This summary was machine generated March 20 at 12:04 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Opus Genetics

See all news